Listar Instituto de Investigación Biomédica da Coruña (INIBIC) por autor "Agostoni, Piergiuseppe"
Mostrando ítems 1-3 de 3
-
A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus
Farmakis, Dimtrios; Agostoni, Piergiuseppe; Baholli, Loant; Bautin, Andrei; Comin-Colet, Josep; Crespo-Leiro, María Generosa; Fedele, Francesco; García-Pinilla, José Manuel; Giannakoulas, George; Grigioni, Francesco; Gruchała, Marcin; Gustafsson, Finn; Harjola, Veli-Pekka; Hasin, Tal; Herpain, Antoine; Iliodromitis, Efstathios K.; Karason, Kristjan; Kivikko, Matti; Liaudet, Lucas; Ljubas-Maček, Jana; Marini, Marco; Masip, Josep; Mebazaa, Alexandre; Nikolaou, Maria; Ostadal, Petr; Põder, Pentti; Pollesello, Piero; Polyzogopoulou, Eftihia; Pölzl, Gerhard; Tschope, Carsten; Varpula, Marjut; Lewinski, Dirk von; Vrtovec, Bojan; Yilmaz, Mehmet Birhan; Zima, Endre; Parissis, John (Elsevier, 2019-12-15)[Abstract] Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being ... -
Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
Adamapoulos, Stamatis; Corrá, Ugo; Laoutaris, Ioannis D.; Pistono, Massimo; Agostoni, Piergiuseppe; Coats, Andrew J.S.; Crespo-Leiro, María Generosa; Cornelis, Justien; Davos, Constantinos H.; Filippatos, Gerasimos; Lund, Lars H.; Jaarsma, Tiny; Ruschitzka, Frank; Seferovic, Petar M.; Schmid, Jean-Paul; Volterrani, Maurizio; Piepoli, Massimo F. (Wiley, 2018-11-26)[Abstract] Exercise training (ET) and secondary prevention measures in cardiovascular disease aim to stimulate early physical activity and to facilitate recovery and improve health behaviours. ET has also been proposed ... -
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
Papp, Zoltán; Álvarez, Julián; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Černý, Vladimir; Comin-Colet; Comin-Colet, Josep; Crespo-Leiro, María Generosa; Delgado-Jiménez, Juan F.; Édes, István; Eremenko, Alexander; Farmakis, Dimitrios; Fedele, Francesco; Fonseca, Candida; Fruhwald, Sonja; Girardis, Massimo; Guarracino, Fabio; Harjola, Veli-Pekka; Heringlake, Matthias; Herpain, Antoine; Heunks, Leo; Husebye, Tryggve; Ivancan, Višnja; Karason, Kristjan; Kaul, Sundeep; Kivikko, Matti; Kubica, Janek; Masip, Josep; Matskeplishvili, Simon; Mebazaa, Alexandre; Nieminen, Markku S.; Oliva, Fabrizio; Papp, Julius G.; Parissis, John; Parkhomenko, Alexander; Põder, Pentti; Pölzl, Gerhard; Reinecke, Alexander; Ricksten, Sven-Erik; Riha, Hynek; Rudiger, Alain; Sarapohja, Toni; Schwinger, Robert H. G.; Toller, Wolfgang; Tritapepe, Luigi; Tschöpe, Carsten; Wikström, Gerhard; Lewinski, Dirk von; Vrtovec, Bojan; Pollesello, Piero; Agostoni, Piergiuseppe (Wolters Kluwer, 2020-07)[Abstract] Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ...